Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies

Blood (2024) 144 (Supplement 1): 914.

https://doi.org/10.1182/blood-2024-210243

Published: 2024

Journal Articles

Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

Steffen Krohn, Carina Lynn Gehlert, Dorothee Winterberg, Alexander Jochimsen, Ammelie Svea Boje, Natalie Baum, Claudia D Baldus, Monika Brüggemann, Gunnar Cario, Martin Schrappe, Lennart Lenk, Martin Gramatzki, Katja Klausz, Christian Kellner, Matthias Peipp

Blood (2024) 144 (Supplement 1): 4173.

https://doi.org/10.1182/blood-2024-207737

Published: 2024

Journal Articles

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4190.

https://doi.org/10.1182/blood-2023-185875

Published: 2023

Journal Articles

Blocking the Don't Eat Me Signal (CD47-SIRPα Axis) to Improve Antibody-Based Immunotherapy of Multiple Myeloma

Katja Klausz, Carina Lynn Gehlert, Ammelie Svea Boje, Marta Lustig, Steffen Krohn, Syeda Maliha Ahmed, Christian Kellner, Thomas Valerius, Lenka Besse, Andrej Besse, Christoph Driessen, Martin Gramatzki, Matthias Peipp

Blood (2021) 138 (Supplement 1): 2684.

https://doi.org/10.1182/blood-2021-152208

Published: 2021

Journal Articles

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

Judith Petersen, Thies Rösner, PhD, Max Kölling, Katja Klausz, PhD, Christian Kellner, PhD, Andreas Humpe, MD, George J Weiner, MD, Denis Martin Schewe, Matthias Peipp, PhD, Thomas Valerius, MD

Blood (2019) 134 (Supplement_1): 5305.

https://doi.org/10.1182/blood-2019-122940

Published: 2019

Journal Articles

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

Thorsten Ross, PhD, Uwe Reusch, PhD, Susanne Wingert, PhD, Torsten Haneke, PhD, Katja Klausz, PhD, Anna-Kathrin Otte, PhD, Natalie Schub, MD, Stefan Knackmuss, PhD, Thomas Müller, Kristina Ellwanger, PhD, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, PhD, Thomas Valerius, MD, Martin Gramatzki, MD, Matthias Peipp, PhD, Michael Tesar, PhD, Erich Rajkovic, PhD MBA, Martin Treder, PhD

Blood (2018) 132 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2018-99-118970

Published: 2018

Journal Articles

Targeting the Glyco-Antigen CD75s with the Tetravalent, Fc-Engineered Antibody 'Ebu-141 Tetra' Induces Potent Killing of B Cell Lymphoma and Plasma Cell Tumors

Katja Klausz, PhD, Amir Karimzadeh-Tabrizi, Malena Buck, Steffen Krohn, Anna-Kathrin Otte, PhD, Christian Kellner, PhD, Giorgio Alberto Croci, MD, Wolfram Klapper, MD, Matthias Peipp, PhD, Martin Gramatzki, MD

Blood (2018) 132 (Supplement 1): 4178.

https://doi.org/10.1182/blood-2018-99-118068

Published: 2018

Journal Articles

CD75s Represents a Therapeutic Target for Antibody-Based Immunotherapy of B Cell Lymphoma and Multiple Myeloma

Katja Klausz, PhD, Malena Buck, Steffen Krohn, Renate Burger, PhD, Christian Kellner, PhD, Martin Gramatzki, MD, Matthias Peipp, PhD

Blood (2017) 130 (Supplement 1): 1810.

https://doi.org/10.1182/blood.V130.Suppl_1.1810.1810

Published: 2017

Journal Articles

AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma

Thorsten Gantke, PhD, Uwe Reusch, PhD, Christian Kellner, PhD, Katja Klausz, PhD, Torsten Haneke, PhD, Stefan Knackmuss, PhD, Thomas Müller, Kristina Ellwanger, PhD, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, PhD, Anne Kerber, MD, Matthias Peipp, PhD, Martin Treder, PhD

Blood (2017) 130 (Supplement 1): 3082.

https://doi.org/10.1182/blood.V130.Suppl_1.3082.3082

Published: 2017

Journal Articles

The Novel ADCC-Optimized Human CD54 (ICAM-1) Antibody MSH-TP15e Has Potent Anti-Myeloma Activity

Katja Klausz, PhD, Renate Burger, PhD, Christian Kellner, PhD, Andreas Guenther, MD, Matthias Peipp, PhD, Martin Gramatzki, MD

Blood (2016) 128 (22): 4471.

https://doi.org/10.1182/blood.V128.22.4471.4471

Published: 2016

Journal Articles

A Novel ICAM-1/CD54 Antibody Identified By Phage Display with Potent Pre-Clinical Anti-Myeloma Activity

Katja Klausz, PhD, Renate Burger, PhD, Christian Kellner, PhD, Matthias Peipp, PhD, Martin Gramatzki, MD

Blood (2014) 124 (21): 2095.

https://doi.org/10.1182/blood.V124.21.2095.2095

Published: 2014

Journal Articles

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

Matthias Peipp, PhD, Christian Kellner, PhD, Andreas Günther, MD, Andreas Humpe, MD, Roland Repp, MD, Katja Klausz, PhD, Stefanie Derer, PhD, Thomas Valerius, MD, Jan G.J. van de Winkel, PhD, Paul W.H.I. Parren, PhD, Martin Gramatzki, MD

Blood (2014) 124 (21): 1779.

https://doi.org/10.1182/blood.V124.21.1779.1779

Published: 2014

Journal Articles

MSH-TP15 Identified By Phage Display Technology Detects a Target Structure For Antibody-Mediated Killing In Multiple Myeloma

Katja Klausz, PhD, Renate Burger, PhD, Christian Kellner, PhD, Pia Glorius, PhD, Andreas Guenther, MD, Matthias Peipp, PhD, Martin Gramatzki, MD

Blood (2013) 122 (21): 4442.

https://doi.org/10.1182/blood.V122.21.4442.4442

Published: 2013

Journal Articles

Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.

Michael Dechant, MD, Stefan Lohse, PhD, Stefanie Derer, PhD, Thomas Beyer, PhD, Katja Klausz, PhD, Matthias Peipp, PhD, Jeanette H. W. Leusen, PhD, Jan G. J. van de Winkel, PhD, Thomas Valerius, MD

Blood (2010) 116 (21): 1488.

https://doi.org/10.1182/blood.V116.21.1488.1488

Published: 2010

NARROW

A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies

Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

Blocking the Don't Eat Me Signal (CD47-SIRPα Axis) to Improve Antibody-Based Immunotherapy of Multiple Myeloma

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

Targeting the Glyco-Antigen CD75s with the Tetravalent, Fc-Engineered Antibody 'Ebu-141 Tetra' Induces Potent Killing of B Cell Lymphoma and Plasma Cell Tumors

CD75s Represents a Therapeutic Target for Antibody-Based Immunotherapy of B Cell Lymphoma and Multiple Myeloma

AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma

The Novel ADCC-Optimized Human CD54 (ICAM-1) Antibody MSH-TP15e Has Potent Anti-Myeloma Activity

A Novel ICAM-1/CD54 Antibody Identified By Phage Display with Potent Pre-Clinical Anti-Myeloma Activity

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

MSH-TP15 Identified By Phage Display Technology Detects a Target Structure For Antibody-Mediated Killing In Multiple Myeloma

Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only